Characteristics and Hospital Outcomes of Patients Admitted to the Intensive Care Unit Because of Haematological Malignancy—A Service Evaluation
eJHaem · 2026-12 · 7 (6)
DOI: 10.1002/jha2.70453 ↗Kurz gefasst
Fachartikel in der Zeitschrift eJHaem, online erschienen am 05.11.2026. Verfasst von Adam Harriman und 4 weiteren Autor:innen. Beteiligte Einrichtung: Therapy Services University Hospitals Birmingham NHS Foundation Trust Birmingham UK. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Intensivpflege
Abstract (Originalsprache)
Introduction
Intensive care unit (ICU) admission due to haematological malignancy (HM) has previously been questioned due to high mortality. While mortality‐associated factors have been studied in HM patients to guide decision making and clinical practice, UK‐based research remains limited. This single‐centre retrospective service evaluation (SE) aimed to review characteristics and hospital outcomes of patients admitted to our ICU because of HM.
Methods
Consecutive adults with HM‐related admissions to a multi‐specialty ICU between January 2022 and October 2024 were retrospectively identified. Data were extracted for patient characteristics, ICU interventions and hospital outcomes. Associations with ICU mortality rates were also assessed.
Results
During the SE, there were 227 ICU admissions of HM patients, of which 168 were HM‐related and, hence, included in subsequent analysis. The most common reasons for admission were respiratory failure (36.3%) and sepsis (26.2%). ICU and in‐hospital mortality rates were 44.0% and 53.0%, respectively. ICU mortality rates increased significantly with APACHE II and SOFA scores (both p < 0.001), and in patients with leukaemia ( p = 0.021), graft versus host disease ( p = 0.001), treatment limitations ( p < 0.001) or that were chemotherapy naïve ( p = 0.044). In patients surviving to ICU discharge, 31.9% were unable to mobilise out of bed at this point. By hospital discharge, 94.9% of surviving patients were mobile; however, 25.3% required ongoing rehabilitation.
Conclusion
This SE describes the characteristics, outcomes and mortality‐associated factors in patients with HM‐related admissions to our ICU, which may be useful in aiding clinician understanding and guiding future practice. Prospective, robust studies are needed to validate findings and explore future opportunities to enhance patient outcomes in this cohort. Trial Registration The authors have confirmed clinical trial registration is not needed for this submission.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Therapy Services University Hospitals Birmingham NHS Foundation Trust Birmingham UK.
- Birmingham Acute Care Research Group Institute of Inflammation and Ageing University of Birmingham Birmingham UK.
- University Hospitals Birmingham NHS Foundation Trust Birmingham UK.
- Research Development and Innovation University Hospitals Birmingham NHS Foundation Trust Birmingham UK.
- College of Health Medicine and Life Sciences Department of Health Sciences Brunel University of London London UK.
ORCID-Profile: Adam Harriman, Vicky MacBean
Zitieren
APA
Harriman, A., Parekh, D., Hodson, J., Weblin, J., & MacBean, V. (2026). Characteristics and Hospital Outcomes of Patients Admitted to the Intensive Care Unit Because of Haematological Malignancy—A Service Evaluation. eJHaem, 7(6). https://doi.org/10.1002/jha2.70453
Vancouver
Harriman A, Parekh D, Hodson J, Weblin J, MacBean V. Characteristics and Hospital Outcomes of Patients Admitted to the Intensive Care Unit Because of Haematological Malignancy—A Service Evaluation. eJHaem. 2026;7(6). doi:10.1002/jha2.70453
BibTeX
@article{Harriman2026,
author = {Harriman, Adam and Parekh, Dhruv and Hodson, James and Weblin, Jonathan and MacBean, Vicky},
title = {Characteristics and Hospital Outcomes of Patients Admitted to the Intensive Care Unit Because of Haematological Malignancy—A Service Evaluation},
journal = {eJHaem},
year = {2026},
volume = {7},
number = {6},
doi = {10.1002/jha2.70453}
}
EUVIMED